KCNK3 and atrial fibrillation: Pharmacological inhibition of TASK-1, using gene therapy approaches or experimental pharmacological inhibitors like A293, has demonstrated potential in preclinical models to restore normal APD and reduce AF incidence without affecting ventricular electrophysiology, offering a pathway for atrial-selective antiarrhythmic therapy [25–28].